https://www.sciencedirect.com/science/article/pii/S0969996119301986?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31301344?dopt=Abstract
TITLE:
Cysteamine as a novel disease-modifying compound for Parkinson’s disease: Over a decade of research supporting a clinical trial.
DESCRIPTION:
Cysteamine as a novel disease-modifying compound for Parkinson’s disease: Over a decade of research supporting a clinical trial.
Neurobiol Dis. 2019 Jul 10;:104530
Authors: Cicchetti F, David LS, Siddu A, Denis HL
Abstract
To date, medical and surgical interventions offered to patients with Parkinson’s disease (PD) serve only to manage clinical symptoms; they have not shown the capacity to halt nor reverse degenerative processes. There is therefore an urgent need to identify and/or develop therapeutic strategies that will demonstrate ‘disease modifying’ capacities. The molecule cystamine, and its reduced form cysteamine, act via a number of pathways identified as being critical to the pathogenesis of PD. In particular, these agents are capable of crossing the blood-brain barrier, promoting the secretion of neurotrophic factors, the inhibition of oxidative stress, the reduction of inflammatory responses and importantly, have already been trialed in humans for a number of other clinical indications. In the last decade, our laboratory has accumulated compelling evidence that both cystamine and cysteamine can halt, and even reverse, ongoing neurodegenerative processes in a number of different models of PD, and as such, should now be taken forward to clinical trials in PD.
PMID: 31301344 [PubMed – as supplied by publisher]
PMID:
PubMed:31301344
DATE FOUND:
07/14/19 06:01AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31301344?dopt=Abstract